Abstract:Abstract Proteolysis-targeting chimeras (PROTACs) are a novel class of small molecules that induce the degradation of target proteins. Unlike conventional inhibitors that disable target proteins by direct binding, PROTACs are event-driven, meaning that a single PROTAC molecule can induce the degradation of multiple target protein molecules. This catalytic mechanism allows PROTACs to achieve complete inhibition of target proteins at lower concentrations compared to conventional inhibitors, making them a promising therapeutic approach for previously considered "undruggable" targets.Despite their promise, the development of PROTACs faces several challenges. The large molecular weight of PROTACs can lead to poor cell permeability and bioavailability. Additionally, the lack of high-throughput, quantitative assays for evaluating PROTAC efficacy hinders structure-activity relationship (SAR) studies. The formation of the Protein-PROTAC-E3 ternary complex is crucial for PROTAC function, and reliable methods for assessing this interaction are essential for PROTAC development.In this poster, ChemPartner showcases a comprehensive suite of preclinical models for PROTAC evaluation, encompassing both in vitro and in vivo approaches. Using low-cost, high-throughput biochemical assays, we can provide valuable insights into PROTAC efficacy, facilitating SAR studies and elucidating the relationship between molecular structure and activity. Followed by in cell and in vivo function assays, we can test PROTAC PK/PD, toxicity, and efficacy. This suite of assays provides a powerful tool to speed up PROTAC development and reduce the fail rate. Citation Format: yuzhou xu, Jichuan Zhang, Ye Tian, Ziyu Chen, Amy Wang, Ting Ma, Qikuan Chen, Yinfei Yin. Novel preclinical models for PROTAC evaluation: And beyond [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2049.

Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers

Discovery of Potent SOS1 PROTACs with Effective Antitumor Activities against NCI-H358 Tumor Cells In Vitro/In Vivo

Design, synthesis, and bioevaluation of SOS1 PROTACs derived from pyrido[2,3- d ]pyrimidin-7-one-based SOS1 inhibitor

Discovery of LHF418 as a new potent SOS1 PROTAC degrader

A One-Pot Photocatalytic Triazole-Based Linkerology for PROTACs

Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras

A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRAS G12C Inhibitor

Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS G12D

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

New-generation advanced PROTACs as potential therapeutic agents in cancer therapy

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment

Novel Amphiphilic PROTAC with Enhanced Pharmacokinetic Properties for ALK Protein Degradation

Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Development of PROTACS degrading KRAS and SOS1

Abstract 2049: Novel preclinical models for PROTAC evaluation: And beyond

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

An overview of PROTACs: a promising drug discovery paradigm